Grace Therapeutics (GRCE) Operating Leases (2020 - 2023)

Grace Therapeutics has disclosed Operating Leases across 3 years of filings, most recently posting $46000.0 for Q3 2023.

• In Q3 2023, Operating Leases fell 89.78% year-over-year to $46000.0; the TTM figure through Sep 2023 stood at $46000.0 (down 89.78% YoY), while the FY2023 annual figure was $485000.0, up 153.93% from the prior year.
• Operating Leases came in at $46000.0 for Q3 2023 at Grace Therapeutics, down from $80000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $485000.0 in Q1 2023 to a low of $38000.0 in Q3 2020.
• Average Operating Leases over 3 years is $202100.0, with a median of $127000.0 recorded in 2022.
• The largest YoY upside for Operating Leases was 153.93% in 2023 against a maximum downside of 89.78% in 2023.
• Over 3 years, Operating Leases stood at $38000.0 in 2020, then soared by 1031.58% to $430000.0 in 2022, then sank by 89.3% to $46000.0 in 2023.
• Per Business Quant data, the three most recent Operating Leases figures were $46000.0 in Q3 2023, $80000.0 in Q2 2023, and $485000.0 in Q1 2023.